Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)
Paris, May 16, 2022 – PKvitality, a French company specializing in Bio-wearable Health and Sports, has been selected to join the 1st promotion of Future4care, the largest eHealth accelerator in Europe. At the forefront of diabetes innovation, PKvitality has developed K’Watch Glucose, the world’s first Continuous Glucose Monitoring (CGM) smartwatch. The acceleration will speed up the development of this unique innovation in diabetes monitoring that takes the form of a smartwatch.
A share ambition: accelerating eHealth
Future4care is Europe’s largest open-innovation ecosystem on healthcare created under the initiative of four leading companies: Capgemini, Generali, Orange, and Sanofi. Its ambition is to support emerging companies in bringing their solutions to market and to accelerate future of healthcare for patients, by making the most of the possibilities of digital technology.
PKvitality’s mission is to enable everyone to be actively involved in their well-being and health through pleasant and straightforward products. PKvitality is developing K’Watch Glucose, the world’s first painless CGM (Continuous Glucose Monitor) smartwatch that will track glucose levels continuously and discreetly. The system will measure glucose levels by analyzing interstitial fluid (ISF) thanks to Skintaste, a patented system using micropoints. The system enables a painless and non-stigmatizing experience in a design-to-cost architecture. Using the same technology, they are developing K’Watch Athlete, a real-time lactate monitoring design that will allow athletes and trainers to significantly improve training and performance while reducing the risk of injuries.
PKvitality’s mission is to enable everyone to contribute actively to their well-being and health through products that are simple and comfortable to use. Thus, its K’Watch Glucose smartwatch will be the world’s first CGM device that will track glucose levels discreetly and continuously at the wrist.
French medtech companies are tackling diabetes and innovating, as proven by the sheer number of patents filed in 2021. Each year, the National Industrial Property Institute (INPI)ranks the top patent filers, highlighting companies that invest in innovation.
Paris, January 28, 2022 – PKvitality, a French company specializing in bio-wearables, finalized a funding round of €6m, including an investment from the EIC Fund (European Innovation Council Fund). Other contributors to this round are Business Angels, EIT Health, alongside current investors on board, including Beurer GmbH. This round will accelerate the development of K’Watch Glucose, a Continuous Glucose Monitor (CGM) embedded in a smartwatch for diabetes patients.
Paris, November 23, 2021 – PKvitality, a French company specialized in Health and Sport bio-wearables today announced the start of a clinical study to determine the accuracy of the K’Watch Glucose. The trial is conducted with the AMCR Institute Inc, a clinical research center focused on diabetes and obesity with worldwide renown medical device expertise in the metabolic area.